Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243790 | 0.82 | ALDH1A1 (0.51) | NR1H4EPHX2SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL3105102 | 0.82 | ADRB3 (0.42) | NR1H4EPHX2MYCPTPRCS1PR1 | |
| SCHEMBL3897985 | 0.81 | NR1H4 (0.62) | NR1H4EPHX2SMN1; SMN2L3MBTL1 | |
| SCHEMBL31019193 | 0.81 | NR1H4 (0.62) | NR1H4EPHX2SMN1; SMN2L3MBTL1 | |
| SCHEMBL2473815 | 0.80 | NR1H4 (0.47) | NR1H4RXRBRXRARARB | |
| SCHEMBL14205020 | 0.79 | KMT2A (0.46) | S1PR1SMN1; SMN2ATM | |
| SCHEMBL5038405 | 0.77 | MEP1B (0.60) | NR1H4MYCSMN1; SMN2 | |
| SCHEMBL734928 | 0.77 | ATM (0.55) | PTPRCSMN1; SMN2ATM | |
| SCHEMBL3117970 | 0.77 | S1PR1 (0.35) | NR1H4EPHX2MYCS1PR1VSIR | |
| SCHEMBL16355776 | 0.76 | LMNA (0.50) | PTPRCS1PR1SMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | NR1H4 788/4885EPHX2 1950/4885RXRB 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.